Jane Street Group LLC bought a new position in shares of Tectonic Therapeutic (NASDAQ:TECX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 29,702 shares of the company's stock, valued at approximately $1,371,000. Jane Street Group LLC owned 0.20% of Tectonic Therapeutic at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Invesco Ltd. acquired a new position in Tectonic Therapeutic in the fourth quarter valued at approximately $5,918,000. Susquehanna International Group LLP increased its stake in Tectonic Therapeutic by 165.2% during the fourth quarter. Susquehanna International Group LLP now owns 166,452 shares of the company's stock worth $7,685,000 after acquiring an additional 103,698 shares during the last quarter. Artia Global Partners LP purchased a new stake in Tectonic Therapeutic in the fourth quarter valued at $769,000. Barclays PLC raised its position in Tectonic Therapeutic by 1,008.5% in the fourth quarter. Barclays PLC now owns 15,974 shares of the company's stock valued at $737,000 after purchasing an additional 14,533 shares during the period. Finally, Clarius Group LLC acquired a new position in shares of Tectonic Therapeutic in the 4th quarter valued at $468,000. 62.63% of the stock is currently owned by institutional investors and hedge funds.
Tectonic Therapeutic Trading Up 11.5%
Shares of NASDAQ TECX opened at $23.41 on Tuesday. The stock has a market capitalization of $437.13 million, a PE ratio of -3.97 and a beta of 3.44. Tectonic Therapeutic has a twelve month low of $13.70 and a twelve month high of $61.07. The stock has a fifty day simple moving average of $19.44 and a 200-day simple moving average of $33.44.
Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.93) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.17. On average, equities analysts predict that Tectonic Therapeutic will post -8.31 earnings per share for the current year.
Insider Activity
In related news, Director Timothy A. Springer bought 3,718 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $14.76 per share, for a total transaction of $54,877.68. Following the completion of the acquisition, the director now owns 4,317,276 shares in the company, valued at approximately $63,722,993.76. This trade represents a 0.09% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders acquired 100,696 shares of company stock valued at $1,705,714. 38.00% of the stock is currently owned by company insiders.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. Mizuho raised their price objective on Tectonic Therapeutic from $51.00 to $85.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. Wells Fargo & Company dropped their price target on shares of Tectonic Therapeutic from $112.00 to $101.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Tectonic Therapeutic presently has an average rating of "Buy" and an average target price of $79.20.
View Our Latest Stock Report on TECX
Tectonic Therapeutic Profile
(
Free Report)
Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tectonic Therapeutic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tectonic Therapeutic wasn't on the list.
While Tectonic Therapeutic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
